Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 101 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Recombinant tissue plasminogen activator (rt-PA) Clear all
Completed Phase 2 Interventional Results available

A Safety/Efficacy Study of Intra-coronary Tenecteplase During Balloon Angioplasty to Treat Heart Attacks

NCT00604695
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Tenecteplase, Sterile Saline
Drug
Lead sponsor
C. Michael Gibson, MS, MD
Other
Eligibility
18 Years to 74 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Gainesville, Florida • Atlanta, Georgia • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2012 · Synced Oct 7, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

Safety of Intravenous Thrombolytics in Stroke on Awakening

NCT01643902
View directory record Official record
Conditions
Stroke
Interventions
tPA
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 7, 2026, 9:35 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

NCT03594175
View directory record Official record
Conditions
Catheter Occlusion, Thrombosis
Interventions
CUSA-081, Placebo, Alteplase
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Little Rock, Arkansas • Redlands, California • Stockton, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 7, 2026, 9:35 AM EDT
Terminated Phase 4 Interventional

A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)

NCT00168792
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Tenecteplase, PCI
Drug · Procedure
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
8
States / cities
Little Rock, Arkansas • Fort Lauderdale, Florida • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 7, 2026, 9:35 AM EDT
Terminated Phase 4 Interventional Results available

Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

NCT04558125
View directory record Official record
Conditions
Pulmonary Embolism, COVID
Interventions
TNKase, Placebo, Enoxaparin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 7, 2026, 9:35 AM EDT
Terminated Phase 3 Interventional Results available

Clot Dissolving Treatment for Blood Clots in the Lungs

NCT00680628
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Tenecteplase + Enoxaparin, 0.9% Saline + Enoxaparin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
7
States / cities
Sacramento, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 7, 2026, 9:35 AM EDT
Not listed Phase 1 Interventional

Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions

NCT02135588
View directory record Official record
Conditions
Loculated or Non-draining Malignant Pleural Effusions
Interventions
Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)
Drug
Lead sponsor
Eastern Regional Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 7, 2026, 9:35 AM EDT
Completed Phase 4 Interventional Results available

Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis

NCT04806373
View directory record Official record
Conditions
Pleural Effusion
Interventions
Cathflo Activase, Talc Slurry Pleurodesis
Drug
Lead sponsor
Memorial Healthcare System
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 7, 2026, 9:35 AM EDT
Completed Phase 3 Interventional Results available

tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden

NCT04248868
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
The Bashir™ Endovascular Catheter, r-tPA
Device · Drug
Lead sponsor
Thrombolex, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 7, 2026, 9:35 AM EDT
Enrolling by invitation Phase 4 Interventional

CleaRRAflow: Isotonic Solution vs. TPA for IVH Clearance

NCT07643493
View directory record Official record
Conditions
Tissue Plasminogen Activator, Intraventricular Brain Hemorrhage
Interventions
Tissue Plasminogen Activator (tPA), Isotonic solution
Drug · Procedure
Lead sponsor
David Dornbos
Other
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 7, 2026, 9:35 AM EDT
Terminated Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke

NCT02072226
View directory record Official record
Conditions
Stroke
Interventions
Alteplase, Alteplase Placebo, Aspirin, Aspirin Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 7, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection

NCT03672006
View directory record Official record
Conditions
Central Venous Catheter Thrombosis, Central Venous Catheter Associated Bloodstream Infection
Interventions
alteplase (recombinant t-PA), Heparin
Biological · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 7, 2026, 9:35 AM EDT
Terminated Not applicable Interventional

Helping Stroke Patients With ThermoSuit Cooling

NCT02453373
View directory record Official record
Conditions
Stroke, Brain Ischemia
Interventions
ThermoSuit Cooling Induction, Magnesium Sulfate, tPA, Propofol, Etomidate, Neurothrombectomy
Device · Drug · Procedure
Lead sponsor
Life Recovery Systems
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
New Orleans, Louisiana • Danville, Pennsylvania • Wilkes-Barre, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 7, 2026, 9:35 AM EDT
Completed Not applicable Interventional

IV vs. IA tPA (Activase) in Acute Ischemic Stroke With CTA Evidence of Major Vessel Occlusion

NCT00624000
View directory record Official record
Conditions
Ischemic Stroke
Interventions
IV tpa (Alteplase) vs IA tpa (Alteplase)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
19 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 7, 2026, 9:35 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

NCT01580618
View directory record Official record
Conditions
Pleural Effusion
Interventions
normal saline, TNK (Tenecteplase)
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 7, 2026, 9:35 AM EDT
Completed Not applicable Interventional

Treatment of Abdominal Abscesses With or Without Fibrinolysis

NCT01597336
View directory record Official record
Conditions
Abdominal Abscess, Tissue Plasminogen Activator
Interventions
Tissue plasminogen activator abscess flush, Saline flush of abscess
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 17 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Oct 7, 2026, 9:35 AM EDT
Completed Phase 4 Interventional Results available

Assess the Penumbra System in the Treatment of Acute Stroke

NCT01429350
View directory record Official record
Conditions
Ischemic Stroke
Interventions
intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Penumbra System
Drug · Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Denver, Colorado • Gainesville, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 7, 2026, 9:35 AM EDT
Completed Phase 3 Interventional Results available

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

NCT00790335
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism, Post Thrombotic Syndrome
Interventions
Recombinant tissue plasminogen activator (rt-PA)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
16 Years to 75 Years
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
56
States / cities
Glendale, Arizona • Orange, California • Stanford, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 7, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins

NCT00082355
View directory record Official record
Conditions
Acute Deep Venous Thrombosis of the Lower Extremity
Interventions
Alteplase (Activase, Genentech)
Drug
Lead sponsor
Richard Chang, M.D.
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 7, 2026, 9:35 AM EDT
Completed Phase 4 Interventional Results available

rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome

NCT02355743
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
rtPA lock therapy
Drug
Lead sponsor
Lynn Malec
Other
Eligibility
6 Months to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 7, 2026, 9:35 AM EDT
Completed Phase 4 Interventional Results available

Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism

NCT02396758
View directory record Official record
Conditions
Pulmonary Embolism and Thrombosis
Interventions
Ekosonic® Endovascular Device ultrasonic infusion catheter, Recombinant tissue plasminogen activator
Device · Biological
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
16
States / cities
Beverly Hills, California • Tallahassee, Florida • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 7, 2026, 9:35 AM EDT
Completed Phase 1 Interventional

Low-Dose rtPA to Treat Blood Clots in Major Arm or Neck Veins

NCT00055159
View directory record Official record
Conditions
Thrombosis
Interventions
Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 7, 2026, 9:35 AM EDT
Not listed Not applicable Interventional

Aureva Transcranial Ultrasound Device With tPA in Patients With Acute Ischemic Stroke

NCT03519737
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
tPA in combination with the Sonolysis Headframe (TUS), tPA in combination with the Sonolysis Headframe (Sham TUS)
Device
Lead sponsor
Cerevast Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Memphis, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 7, 2026, 9:35 AM EDT
Completed No phase listed Observational

Early Mobilization of Ischemic Stroke Patients Within 24-hours After Intravenous-Tissue Plasminogen Activator (IV-tPA)

NCT01331200
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 7, 2026, 9:35 AM EDT